Opioid Resource Center

Opioid Resource Center

May 18, 2018
1 min read

Buprenorphine depot formulations effective for opioid use disorder

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Long-acting subcutaneous depot buprenorphine formulations conferred more opioid-negative urine samples and a better response rate among adults with opioid use disorder than sublingual buprenorphine-naloxone, according to a new study published in JAMA Internal Medicine.

Buprenorphine treatment for opioid use disorder may be improved by sustained-release formulations,” Michelle R. Lofwall, MD, from the Center on Drug and Alcohol Research at the University of Kentucky, and colleagues wrote.

Lofwall and colleagues conducted a randomized clinical trial to compare the efficacy of weekly and monthly subcutaneous buprenorphine depot formulations with a daily sublingual combination of buprenorphine hydrochloride and naloxone hydrochloride for treating opioid use disorder.

The researchers enrolled 428 adults with moderate-to-severe opioid use disorder (61.4% men; mean age, 38.4 years) and randomly assigned 215 to receive daily sublingual buprenorphine-naloxone and matched weekly and monthly subcutaneous placebo injections and 213 to receive daily sublingual placebo and weekly and monthly subcutaneous buprenorphine.

Results showed a 3% difference (95% CI, –4 to 9.9) in response rates between the sublingual buprenorphine-naloxone group (14.4%) and the subcutaneous buprenorphine group (17.4%). Opioid-negative urine samples were observed in 28.4% of patients in the sublingual buprenorphine-naloxone group and 35.1% of those in the subcutaneous buprenorphine group (6.7% difference; 95% CI, –0.1 to 13.6).

Evidence for no illicit opioid use, as measured by a cumulative distribution function, was statistically superior among patients in the subcutaneous buprenorphine group, compared with those in the sublingual buprenorphine-naloxone group. Approximately 22% of participants in the sublingual buprenorphine-naloxone group demonstrated signs of injection site adverse events, as did about 19% of those in the subcutaneous buprenorphine group. No adverse events were severe.

“These results support the efficacy of long-acting weekly and monthly subcutaneous depot buprenorphine formulations as an additional [opioid use disorder] treatment option,” Lofwall and colleagues concluded. “These formulations may also address potential limitations and concerns about daily dosing, including diversion, misuse and accidental exposure of medication to children.” – by Alaina Tedesco

Disclosure: Lofwall reports receiving research funding from Braeburn Pharmaceuticals, Inc., and consulting fees from Braeburn Pharmaceuticals, Inc., and Indivior. Please see study for all other authors’ relevant financial disclosures.